Amphastar Pharmaceuticals (AMPH) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$0.91

Estimate

$0.61

Surprise

+48.3%

Revenue (period 2026-06-30)

$183.9M

Score at report (before → after)

5.9 → 5.9/10

Revenue source: xbrl.

Amphastar Pharmaceuticals (AMPH) beat the $0.61 estimate with diluted EPS of $0.91 — a large 48.3% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.9/10) to Sell at 5.9/10 after the report.

TrendMatrix currently rates AMPH Sell at 5.4/10.

2 of the last 4 quarters beat the estimate; this quarter's +48.3% surprise compares with a -0.0% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$21.60

Price target

$22.19

Stop

$20.09

Upside to target

+2.7%

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$918.8M

P/E (fwd)

6.8

P/E (ttm)

12.9

52-week range

$16.65–$31.26

Off 52-week high

30.9%

RSI (14)

64

Volume vs avg

0.81×

Score today

5.4/10